ing the possibility that the genetic aberration leading to AS is situated in a non-exonic region or that the mutation is somatic and not detectable by our approach. Alternatively, it is possible that AS is genetically heterogeneous and that 11 patients are not sufficient to reveal the causative genes. Future studies of AS should consider designs where also non-exonic regions are explored and apply a sequencing depth so that also low-grade somatic mosaicism can be detected.
During the past decades, technological advances have revolutionized the field of genetics. Massively parallel sequencing has been used in several studies to identify mutations underlying rare Mendelian disorders [Ng et al., 2010; Guerreiro et al., 2014] . In particular, analysis of trios has been successful in finding de novo mutations in sporadic neurodevelopmental disorders [Epi4K Consortium et al., 2013; Veeramah et al., 2013] .
In this study, we applied whole-exome sequencing in 11 Aicardi females in search for a shared disease gene. Furthermore, 2 of the patients in the cohort were analyzed together with their parents, making a detection of de novo mutations possible.
Patients and Methods

Patients
Eleven patients with the diagnosis of AS were identified through a collaborative network involving different European neuropediatric epilepsy centers with the following inclusion criteria: (1) infantile seizures, (2) chorioretinal lacunae, and (3) agenesis of the corpus callosum (total or partial). Additional symptoms supportive of AS were: occurrence of malformations of cortical development, gross hemispheric asymmetry, vertebral and costal abnormalities, microphthalmia as well as other eye structural abnormalities. All patients were unrelated and of European ancestry. Clinical features of the patients are summarized in table 1 .
Exome Sequencing
Whole-exome sequencing of 11 patients with AS and 2 pairs of parents (15 individuals) was performed on genomic DNA from whole blood ( fig. 1 ). The exome was enriched by using the Agilent SureSelect Human All Exon Capture kit (50 Mb v.3 and v.5). Sequencing was performed with 100-bp paired-end reads on an Illumina HiSeq2000, yielding an average coverage above 100× (10 samples), and ∼ 40× (5 samples).
Bioinformatic Pipeline
For all 15 samples, the reads were aligned to the reference human genome (hg19) by using Novoalign (Version 2.07.17, http:// www.novocraft.com). The alignments were refined by the Genome Analysis Toolkit (GATK, Version 2.8-1-g932cd3a) [McKenna et al., 2010; DePristo et al., 2011] and PCR duplicates were removed by Picard (Version 1.74, http://broadinstitute.github.io/ picard). Eighty-six percent of the reads mapped uniquely to the reference sequence. Joint variant calling was performed on trios and probands by using GATK. Finally, variant annotation was done using ANNOVAR (2012May25) [Wang et al., 2010] .
Bioinformatic Analysis of Alleles with Low Frequencies
In order to detect possible somatic mutations, the data from the X chromosome was also scrutinized for variants with a low allele ratio, following the approach described by Tapper et al. [2014] . In this approach, alignment was performed by Novoalign (Version 3.02.00), while PCR duplicates removal and variant calling was done using SAMtools (Version 1.19) [Li, 2011] with a flat distribution of initial allele frequency spectrum. The variants were filtered on alternate base count (minimum 3), strand bias, base quality bias, mapping quality bias, and end distance bias. The alternate base should be aligned on both strands [Tapper et al., 2014] .
Filtering of Variants, de novo Analysis, and Analysis Approach
An overview of analysis approaches is given in figure 1 . The variants were considered to be rare if they were absent from or had a frequency <0.01 in the publicly available databases (1000 Genomes Project, ESP, and ExAC) and in our in-house database with variants from 430 exomes. To identify potentially damaging variants, we focused our analysis on nonsynonymous variants, splice site variants, and deletions or insertions causing a frameshift. We excluded variants of low quality and variants in genes known to harbor false positives [Fuentes Fajardo et al., 2012] . For variant filtering and de novo analysis, we used the program FILTUS [Vigeland et al., 2016] . Potential pathogenic variants were prioritized by scores obtained from PolyPhen2, MutationTaster, and GERP.
Results
After analysis of the X chromosome, SLC7A3 was the only remaining candidate gene containing rare variants with pathogenic predictions in 2 individuals. Validation by Sanger sequencing revealed that one variant was inherited from the father, whereas the other could not be validated by Sanger. To evaluate the quality and reliability of this variant, the exome data in the region surrounding the variant was inspected in the Integrative Genomics Viewer, where the variant was observed in 3/20 reads of good quality (online suppl. fig. 1 ; see www. karger.com/doi/10.1159/000448367 for all online suppl. material).
In the autosomes, a gene where >5 patients shared rare potentially damaging variants was not identified. In the de novo analysis of the 2 trios, only 1 variant was identified in 1 trio, a heterozygous mutation in neuronal pas domain protein 2 (NPAS2) (NM_002518:c.2465C>T, p.P822L). We could not detect any de novo variants in the other trio, or any de novo variants in the X chromosome. None of the remaining 11 patients had rare potentially pathogenic variants in the NPAS2 gene. De novo variants of uncertain clinical significance in TEAD1 and OCEL1 have recently been reported in Aicardi patients [Schrauwen et al., 2015] , so particular analysis of these genes were performed. However, no rare variants were observed in any of our patients.
A complete list of all missense/nonsense/splice variants shared by at least 3 patients and with frequency <1% in 1000GP and ESP6500 is provided in online supplementary table 1. 
Discussion
Whole-exome sequencing of 11 affected individuals, including de novo analysis of 2 trios, did not reveal the underlying genetic etiology of AS. Our approach was based on the assumptions that AS is a relatively homogeneous genetic disorder and that the disease-causing variant is a germline point mutation residing in an exon.
The only remaining candidate gene after filtering and analysis was the SLC7A3 gene. This gene encodes a sodium-independent cationic amino acid transporter, CAT-3, which is a member of the solute carrier family 7 [Verrey et al., 2004] . Studies of CAT-3 expression in brain development are conflicting; however, a recent study reported expression in the mouse brain during embryonic development [Nava et al., 2015] . Variation in the SLC7A3 gene is sparse, and loss-of-function variants are completely absent in the ExAC database (http://exac.broadinstitute.org/ gene/ENSG00000165349), demonstrating the importance of a functioning CAT-3 protein. Nonetheless, several patients, including one 46,XY male with a nonlethal phenotype, have been reported to have deletions encompassing the SLC7A3 gene in the DECIPHER database of copy number variations (https://decipher.sanger.ac.uk/). In our study, we found 2 patients with missense variants which are absent in all public databases and which have never previously been described. The substituted amino acids are highly conserved, and in silico predictions suggest severe effects on the function of the protein. However, one of the variants was detected by our low allele frequency approach and could not be validated by Sanger sequencing. As the variant was found in 3 out of only 20 reads, we were unable to conclude whether this was a true somatic variant or a false-positive finding. Thus, whether somatic mutations in this gene are involved in AS remains to be explored, and will probably require a study design with more patients and a sequencing depth that permits detection of somatic mutations with a lower allele frequency.
Trio analysis and detection of de novo mutations has previously been performed in 10 patients with AS [Schrauwen et al., 2015] . In 2 patients, they identified a de novo variant of interest, and suggested TEAD1 and OCEL1 as candidate genes for involvement in AS. We investigated our patients for all variants in these genes; however, none of the variants had a frequency below 0.01 in the public databases. The trio analysis in our study retrieved only one de novo variant in the NPAS2 gene . This variant has a population frequency of 0.003 in the ExAC database and has even been observed in in a homozygous state 9 times, making it unlikely that it is monogenically involved in AS.
This study shows that the etiology of AS will most probably not be found by a regular exome sequencing approach of patients. There are several potential explanations for this. One possibility is that AS is genetically heterogeneous and maybe even not X-linked after all. A non-X-linked cause of AS has been suggested previously, partly due to a lack of nonrandom X chromosome inactivation, which would be expected in a disorder with an X-linked genetic defect [Wang et al., 2009] . However, this is not always present in X-linked disorders, such as e.g., Rett syndrome [Ropers et al., 1982; Yilmaz et al., 2007; Morleo and Franco, 2008] . Furthermore, a causal mutation in an autosomal gene with a sex-limited effect that causes AS in females has also been suggested [Prontera et al., 2013] . In the case of an autosomal dominant inheritance combined with strong genetic heterogeneity, our study design would probably fail to detect the genetic origin. Also, additional technical limitations are to be considered. Whole-exome sequencing has limitations regarding coverage [Gilissen et al., 2014] and causative variants outside of the targeted exome; indels, copy number variations, inversions, or translocations can remain undetected. Furthermore, despite our efforts to also discover somatic mutations in our data, our analysis was limited by both the read depth in our study, where only variants with an allele frequency of ∼ 0.10 or higher would be detected, and also by the availability of only DNA from whole blood, in which the mutation may not even be present. Results from a study of somatic mutations in tuberous sclerosis complex showed that a majority of the patients with somatic mosaicism had an allele frequency <0.10 in blood [Tyburczy et al., 2015] .
Conclusions
In this study, exome sequencing failed to identify the genetic cause of AS. Future studies should aim at designs where also non-exonic regions are explored and apply a sequencing depth where low-grade somatic mosaicism can be detected.
